Related Experiment Video
Updated: Feb 11, 2026

Canine Intestinal Organoids in a Dual-Chamber Permeable Support System
Published on: March 2, 2022
Phase I/II evaluation of RV1001, a novel PI3Kδ inhibitor, in spontaneous canine lymphoma
Heather L Gardner1, Sarah B Rippy2, Misty D Bear3
1Sackler School of Graduate Biomedical Sciences, Tufts University, Boston, Massachusetts, United States of America.
Background:
RV1001 is a novel, potent, and selective PI3Kδ inhibitor. The purpose of this study was to evaluate the safety and efficacy of RV1001 in canine Non-Hodgkin lymphoma (NHL).
Methods And Results:
Inhibition of endogenous pAKT by RV1001 in primary canine NHL cells was determined by Western blotting. A phase I study of RV1001 was performed in 21 dogs with naïve and drug resistant T and B-cell NHL to assess safety, pharmacokinetic profile, and response to therapy. The objective response rate was 62% (complete response (CR) n = 3; partial response (PR) n = 10), and responses were observed in both naïve and chemotherapy-resistant B and T cell NHL. This study provided the recommended starting dose for a phase II, non-pivotal, exploratory, open label multi-centered clinical trial in 35 dogs with naïve and drug resistant T and B-cell NHL, to further define the efficacy and safety profile of RV1001. The objective response rate in the phase II study was 77% (CR n = 1; PR n = 26). Clinical toxicities were primarily hepatobiliary and gastrointestinal, and were responsive to dose modifications and/or temporary drug discontinuation. Hepatotoxicity was the primary dose limiting toxicity.
Conclusions:
RV1001 exhibits good oral bioavailability, an acceptable safety profile, and biologic activity with associated inhibition of pAKT in dogs with B and T cell NHL. Data from these studies can be leveraged to help inform the design of future studies involving isoform-selective PI3K inhibitors in humans.
Insights
RV1001, a PI3Kδ inhibitor, demonstrated significant efficacy and an acceptable safety profile in canine Non-Hodgkin lymphoma (NHL) studies. This novel drug showed promising response rates in both naive and resistant B and T-cell NHL cases.
Area of Science:
- Oncology
- Pharmacology
- Veterinary Medicine
Background:
- Non-Hodgkin lymphoma (NHL) is a significant concern in canine oncology.
- PI3Kδ (Phosphoinositide 3-kinase delta) is a key signaling pathway implicated in various lymphomas.
- Novel therapeutic strategies targeting PI3Kδ are being explored for canine NHL.
Purpose of the Study:
- To evaluate the safety and efficacy of RV1001, a novel PI3Kδ inhibitor, in dogs with Non-Hodgkin lymphoma (NHL).
- To determine the recommended starting dose for further clinical trials in canine NHL.
- To assess the pharmacokinetic profile and therapeutic response to RV1001.
Main Methods:
- Inhibition of pAKT by RV1001 in primary canine NHL cells was assessed using Western blotting.
- A Phase I clinical trial involved 21 dogs with naïve and drug-resistant T and B-cell NHL.
- A subsequent Phase II exploratory trial included 35 dogs to further define efficacy and safety.
Main Results:
- Phase I study showed an objective response rate of 62% (3 CR, 10 PR) in canine NHL.
- Phase II study reported an objective response rate of 77% (1 CR, 26 PR).
- Clinical toxicities were mainly hepatobiliary and gastrointestinal, with hepatotoxicity as the dose-limiting toxicity.
Conclusions:
- RV1001 demonstrated good oral bioavailability, an acceptable safety profile, and biological activity in canine B and T-cell NHL.
- The drug effectively inhibited pAKT, a key signaling molecule, in canine lymphoma.
- Findings support the potential of RV1001 and inform future human clinical trial designs for PI3K inhibitors.
Related Concept Videos
Spontaneity
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Phase Diagrams
Phase Transitions
Spontaneous and Induced Mutations
Inductance: Single-Phase And Three-Phase Line
Single-Phase Two-Wire Line:
A single-phase line consists of two solid cylindrical conductors, denoted as x and y. Each conductor carries phasor currents ix and iy, respectively. Given that the sum of these currents is...

